Advances in the Use of Immune Checkpoint Inhibitors to Treat Non-Melanoma Skin Cancers: Updates for Oncology Pharmacists

This activity was originally broadcast on November 12, 2022 as part of the Directions in Oncology Pharmacy virtual conference series.

Program Description

Non-melanoma skin cancers, including cutaneous squamous cell and basal cell carcinomas, are a diverse group of malignancies with distinct clinical presentations and pathophysiological characteristics. Immune checkpoint inhibitors (ICIs) have advanced the treatment landscape for non-melanoma skin cancers, with several innovative therapeutic strategies and ICI combinations available. However, ICIs are associated with immune-related adverse events (irAEs) and can affect a broad range of organs, including the skin. With the increasing use of ICIs in the treatment of non-melanoma skin cancers, oncology pharmacists must be familiar with dermatological irAEs and management strategies to improve treatment outcomes while minimizing treatment interruptions and discontinuations in patients with non-melanoma skin cancers.

Target audience: Oncology pharmacists

Type of activity: Knowledge
Release date: November 30, 2022
Expiration date: November 30, 2023

Time to complete activity: 0.75 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Describe the pathophysiology and risk factors associated with non-melanoma skin cancers
• Review the evolving role of immune checkpoint inhibitors (ICIs) for the treatment of patients with advanced or metastatic cutaneous squamous cell carcinoma or basal cell carcinoma
• Outline strategies to decrease cutaneous immune-related adverse events associated with ICI therapy

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-22-590-H01-P. The activity is available for CE credit through November 30, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Theresa S. Brown, PharmD, BCOP, CPP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Evelina Kolychev, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms